Tirzepatide vs Semaglutide: Mechanism Compared
Semaglutide and tirzepatide anchor the modern incretin research class. The difference is whether one incretin receptor is engaged, or two.
| Tirzepatide | Semaglutide | |
|---|---|---|
| Receptor targets | GIP + GLP-1 | GLP-1 only |
| Class | Dual receptor agonist | Single-target GLP-1 agonist |
| Distinguishing arm | Adds the GIP receptor | GLP-1 baseline |
| Role in the class | Bridge to the multi-agonists | The most-studied anchor |
Semaglutide acts on a single incretin receptor, GLP-1. Tirzepatide acts on two, adding the GIP receptor in the same molecule — which is what makes it a dual agonist rather than a more potent GLP-1 drug.
Because semaglutide is the single-target baseline of the class, it is the comparator the multi-receptor compounds are measured against in the research literature. Tirzepatide is the first step beyond it, and retatrutide adds a third receptor on top.
The useful framing for research is the receptor count, not a ranking: semaglutide (GLP-1) → tirzepatide (GIP + GLP-1) → retatrutide (GIP + GLP-1 + glucagon).
This compares molecular mechanism and receptor class from the published literature only, not efficacy, potency, or outcomes. All Boulder Labs products are for laboratory research use only. Not for human consumption.
Common questions
What is the difference between tirzepatide and semaglutide?
Semaglutide is a single-target GLP-1 receptor agonist. Tirzepatide is a dual agonist that also activates the GIP receptor. The added GIP-receptor activity is the defining pharmacological difference.
Is tirzepatide just a stronger semaglutide?
No — they are different classes. Tirzepatide engages a second incretin receptor (GIP) that semaglutide does not, so it is a dual agonist rather than a higher-potency single agonist.